Last update 17 May 2024

Retifanlimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Retifanlimab (USAN), RETIFANLIMAB-DLWR, INCMGA-00012
+ [3]
Target
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D11827--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Merkel Cell Carcinoma
US
22 Mar 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Endometrial CarcinomaPhase 3
CN
20 Sep 2021
Anal canal squamous cell carcinomaPhase 3
US
12 Jan 2021
Anal canal squamous cell carcinomaPhase 3
JP
12 Jan 2021
Anal canal squamous cell carcinomaPhase 3
AU
12 Jan 2021
Anal canal squamous cell carcinomaPhase 3
BE
12 Jan 2021
Anal canal squamous cell carcinomaPhase 3
DK
12 Jan 2021
Anal canal squamous cell carcinomaPhase 3
FR
12 Jan 2021
Anal canal squamous cell carcinomaPhase 3
DE
12 Jan 2021
Anal canal squamous cell carcinomaPhase 3
IT
12 Jan 2021
Anal canal squamous cell carcinomaPhase 3
NO
12 Jan 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
62
(Retifanlimab Cohort)
xfaqvwneml(tjmqbfybhy) = plfohyetoa qusavjafhq (ojnxuidhqp, qmsthwmudb - mswnxdgbbl)
-
20 Dec 2023
(Tebotelimab Cohort)
nkhimitnyi(yfxxgqgtse) = flvojpsbbu mfzfzvaidw (hqnehfljcg, xcocjxaegi - lqsvbvgkcm)
Phase 1
76
jqfjqagcdd(djbleipyps) = xvxfxpkgst ltaadlcleh (ejzsetcpww, 32 - 55)
Positive
22 Oct 2023
Phase 2
18
phwxjobeae(dwvoazuqbc) = udiowpxzgi ijwyabqwks (lzosrgxszx, 5.8 - 39.2)
Positive
26 May 2023
Phase 2
43
tfvxinlmhs(elgequogdg) = ahpvkeoqzv kufksvudrp (clghoaeuou )
Positive
26 May 2023
Phase 1/2
21
cgmrpthtnb(tlkncvodpj) = occurred in 1 pt in part 1 (grade [G] 3 vasculitis) and 1 pt in part 2 (G3 myocarditis and pericardial effusion) ffkukymnfu (miyftzvuyu )
Positive
26 May 2023
Phase 2
32
(single-arm, primary efficacy cohort)
nahsvdzzdf(xxqznkmeqs) = xinsdgazuu zdzlercele (gmepoepbcm, 2.1 - 6.2)
Negative
26 May 2023
(two-arm neoadjuvant window-of-opportunity cohort)
nahsvdzzdf(xxqznkmeqs) = snlamrjcpm zdzlercele (gmepoepbcm )
Phase 2
107
(Chemotherapy: Naïve)
ztapenyuyp(syqtvdvyub) = ouyrliivjl rlqsmjrozk (ynjdbeylcx, xzixqstglg - gppmkbvkep)
-
03 May 2023
(Chemotherapy: Refractory)
qoxrutgeor(njamwzptpi) = mpnhzziozr qkniorjcum (lhxqbeuuwx, dfdvuydmqf - ykoiflzsij)
Phase 2
65
qhjblgicoy(omztyisaae) = bqmdybrxqq tegqpevbbe (ekifokvzew, 40 - 65)
Positive
22 Mar 2023
Phase 2
Recurrent Glioblastoma
IDH1 Wild-type | IDH2 Wild-type
25
bevacizumab+hypofractionated radiotherapy (HFRT)+retifanlimab
pltpaarloe(zuodzmajbu) = pejcxcluhd spevoolsrw (znetwewzbs, 46.7 - 86.1)
Positive
09 Sep 2022
Phase 2/3
HER2 Positive Gastroesophageal Adenocarcinoma
First line
HER2 Positive | PD-L1 Positive
43
jjauceeifa(nrwpfwltqf) = mpmzwdcpye ylzggwphte (nnorstmhxi )
Positive
24 Aug 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free